Author Archives: admin


Long weekend reads: What are the risks of rushing a vaccine? 1976 offers some troubling warnings. – The Daily Briefing

September 4, 2020 Ben Palmer's reads

Devo co-founder Mark Mothersbaugh had Covid-19and some 'very dark' delusions. Mark Mothersbaugh, co-founder of the band Devo, was hospitalized with Covid-19 in May, and in a recent interview with the Los Angeles Times, Mothersbaugh opened up about his experiencing fighting the disease while on a ventilator in the ICU. Mothersbaugh talks about the "very dark" delusions he experienced while in the hospital, including believing he was in the ICU because someone had hit him in the head with a brick. "I felt blood from being hit," he said. "I was handcuffed to a parking deck downtown. I had this whole elaborate story of how these kids sold me to an ambulance company that then got some sort of payment for delivering Covid patients to their ICUs. I totally believed it."

The century-long history of convalescent plasma. Convalescent plasma has garnered a lot of attention in recent weeksand last month, FDA in a controversial move issued an emergency use authorization for the therapy as potential treatment for Covid-19. Writing for the Smithsonian Magazine, Jillian Mock examines the history of convalescent plasma, which dates back to the late 19th and early 20th century, when it was used to treat measles, Spanish influenza, and a variety of other diseases.

What can happen when you fast-track a vaccine approval? History lends a forbidding answer. Writing in the New York Times, Rick Perlstein explains what happened during the 1976 election year, when former President Gerald Ford accelerated the development and approval of a vaccine against a new strain of the H1N1 viruswhich appeared to be related to the pathogen that caused the 1918 flu pandemic. The vaccine, which the federal government distributed through a mass vaccination campaign, had unexpected side effects. An estimated 450 of the 45 million Americans who were inoculated with the new vaccine developed a rare disorder called Guillain-Barr syndrome, which paralyzes the body, including 30 who died. In the end, the federal government ended its mass vaccination campaignand Ford lost the election.

Scientists discover a key to a longer and healthier lifefor mice. A study published Tuesday in Cell Metabolism showed mice that were given a naturally occurring metabolite were healthier overall, and sicker for shorter periods before dying, when compared with mice in a control group. For the study, scientists at the Buck Institute for Research on Aging evaluated the effects of a metabolite called alpha-ketoglutarate (AKG)which is naturally found in the body and a plays a role in several biological process, including stem cell growthon 18-month-old mice, meaning they were approximately between ages 55 to 66 in human years. The scientists said they hope their research will pave the way for studies on therapies that could improve quality of life among elderly humans.

Continue reading here:
Long weekend reads: What are the risks of rushing a vaccine? 1976 offers some troubling warnings. - The Daily Briefing

Cell Therapy Market Brief Analysis and Application, Growth by 2026 – Scientect

LOS ANGELES, United States: QY Research has recently published a report, titled Global Cell Therapy Market Professional Survey Report 2020. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Cell Therapy market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Cell Therapy market include: Gilead Sciences Novartis Osiris Vericel Corporation Vcanbio Fujifilm Cellular Dynamics JCR Pharmaceuticals Beike Biotechnology Golden Meditech Guanhao Biotech Segment by Type, , , Stem Cell Non-Stem Cell Segment by Application Hospital Clinic Other By Region North America Europe Japan China Southeast Asia India

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1916335/global-cell-therapy-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Cell Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Cell Therapy Market Segment By Type:

Stem Cell Non-Stem Cell

Global Cell Therapy Market Segment By Application:

Market Analysis and Insights: Global Cell Therapy Market The global Cell Therapy market was valued at US$ 77485 million in 2019 and it is expected to reach US$ 362235 million by the end of 2026, growing at a CAGR of 27.18% during 2020-2026. Global Cell Therapy Scope and Market Size Cell Therapy market is segmented by players, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Cell Therapy market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyzes the impact of Coronavirus COVID-19 on the Cell Therapy industry. By Company Gilead Sciences Novartis Osiris Vericel Corporation Vcanbio Fujifilm Cellular Dynamics JCR Pharmaceuticals Beike Biotechnology Golden Meditech Guanhao Biotech Segment by Type

Stem Cell Non-Stem Cell Segment by Application Hospital Clinic Other By Region North America Europe Japan China Southeast Asia India

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Cell Therapy market.

Key companies operating in the global Cell Therapy market include Gilead Sciences Novartis Osiris Vericel Corporation Vcanbio Fujifilm Cellular Dynamics JCR Pharmaceuticals Beike Biotechnology Golden Meditech Guanhao Biotech Segment by Type, , , Stem Cell Non-Stem Cell Segment by Application Hospital Clinic Other By Region North America Europe Japan China Southeast Asia India

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1916335/global-cell-therapy-market

TOC

1 REPORT OVERVIEW1 1.1 Study Scope1 1.2 Key Market Segments1 1.3 Players Covered: Ranking by Cell Therapy Revenue2 1.4 Market Analysis by Type2 1.4.1 Global Cell Therapy Market Size Growth Rate by Type: 2020 VS 20262 1.4.2 Stem Cell4 1.4.3 Non-Stem Cell5 1.5 Market by Application6 1.5.1 Global Cell Therapy Market Share by Application: 2020 VS 20266 1.5.2 Hospital8 1.5.3 Clinic8 1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth9 1.6.1 How the Covid-19 is Affecting the Cell Therapy Industry9 1.6.2 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections11 1.6.3 Covid-19 Impact: Commodity Prices Indices20 1.6.4 Covid-19 Impact: Global Major Government Policy25 1.6.5 Proposal for Cell Therapy Players to Combat Covid-19 Impact29 1.7 Study Objectives31 1.8 Years Considered31 2 GLOBAL GROWTH TRENDS32 2.1 Global Cell Therapy Market Perspective (2015-2026)32 2.2 Cell Therapy Growth Trends by Regions33 2.2.1 Cell Therapy Market Size by Regions: 2015 VS 2020 VS 202633 2.2.2 Cell Therapy Historic Market Size by Regions (2015-2020)35 2.2.3 Cell Therapy Forecasted Market Size by Regions (2021-2026)35 2.3 Industry Trends and Growth Strategy37 2.3.1 Market Top Trends37 2.3.2 Market Drivers37 2.3.3 Market Challenges38 2.3.4 Porter Five Forces Analysis39 2.3.5 Advantages of Allogeneic Over Autologous Cell Therapy Products40 3 COMPETITION LANDSCAPE BY KEY PLAYERS42 3.1 Global Top Cell Therapy Players by Market Size42 3.1.1 Global Top Cell Therapy Players by Revenue (2019-2020)42 3.1.2 Global Cell Therapy Revenue Market Share by Players (2019-2020)43 3.1.3 Global Cell Therapy by Company Type (Tier 1, Tier 2 and Tier 3)44 3.2 Global Cell Therapy Market Concentration Ratio44 3.2.1 Global Cell Therapy Market Concentration Ratio (CR5)44 3.2.2 Global Top 5 Companies by Cell Therapy Revenue in 201945 3.3 Cell Therapy Key Players Head office and Area Served45 3.4 Key Players Cell Therapy Product Solution and Service46 3.5 Date of Enter into Cell Therapy Market46 3.6 Mergers & Acquisitions, Expansion Plans47 4 CELL THERAPY BREAKDOWN DATA BY TYPE (2015-2026)51 4.1 Global Cell Therapy Historic Market Size by Type (2015-2020)51 4.2 Global Cell Therapy Forecasted Market Size by Type (2021-2026)52 5 CELL THERAPY BREAKDOWN DATA BY APPLICATION (2015-2026)54 5.1 Global Cell Therapy Historic Market Size by Application (2015-2020)54 5.2 Global Cell Therapy Forecasted Market Size by Application (2021-2026)55 6 NORTH AMERICA57 6.1 North America Cell Therapy Market Size (2015-2026)57 6.2 Cell Therapy Key Players in North America (2019-2020)57 6.3 North America Cell Therapy Market Size by Type (2015-2020)58 6.4 North America Cell Therapy Market Size by Application (2015-2020)59 7 EUROPE60 7.1 Europe Cell Therapy Market Size (2015-2026)60 7.2 Cell Therapy Key Players in Europe (2019-2020)60 7.3 Europe Cell Therapy Market Size by Type (2015-2020)61 7.4 Europe Cell Therapy Market Size by Application (2015-2020)61 8 JAPAN63 8.1 Japan Cell Therapy Market Size (2015-2026)63 8.2 Cell Therapy Key Players in Japan (2019-2020)63 8.3 Japan Cell Therapy Market Size by Type (2015-2020)64 8.4 Japan Cell Therapy Market Size by Application (2015-2020)64 9 CHINA66 9.1 China Cell Therapy Market Size (2015-2026)66 9.2 Cell Therapy Key Players in China (2019-2020)66 9.3 China Cell Therapy Market Size by Type (2015-2020)67 9.4 China Cell Therapy Market Size by Application (2015-2020)67 10 SOUTHEAST ASIA69 10.1 Southeast Asia Cell Therapy Market Size (2015-2026)69 10.2 Cell Therapy Key Players in Southeast Asia (2019-2020)69 10.3 Southeast Asia Cell Therapy Market Size by Type (2015-2020)70 10.4 Southeast Asia Cell Therapy Market Size by Application (2015-2020)70 11 INDIA72 11.1 India Cell Therapy Market Size (2015-2026)72 11.2 Cell Therapy Key Players in India (2019-2020)72 11.3 India Cell Therapy Market Size by Type (2015-2020)73 11.4 India Cell Therapy Market Size by Application (2015-2020)73 12 KEY PLAYERS PROFILES75 12.1 Gilead Sciences75 12.1.1 Gilead Sciences Company Details75 12.1.2 Gilead Sciences Cell Therapy Introduction76 12.1.3 Gilead Sciences Revenue in Cell Therapy Business (2019-2020)76 12.2 Novartis77 12.2.1 Novartis Company Details77 12.2.2 Novartis Cell Therapy Introduction78 12.2.3 Novartis Revenue in Cell Therapy Business (2019-2020)79 12.3 Osiris79 12.3.1 Osiris Company Details79 12.3.2 Osiris Cell Therapy Introduction80 12.3.3 Osiris Revenue in Cell Therapy Business (2019-2020)81 12.4 Vericel Corporation81 12.4.1 Vericel Corporation Company Details81 12.4.2 Vericel Corporation Cell Therapy Introduction82 12.4.3 Vericel Corporation Revenue in Cell Therapy Business (2019-2020)83 12.5 Vcanbio83 12.5.1 Vcanbio Company Details83 12.5.2 Vcanbio Cell Therapy Introduction84 12.5.3 Vcanbio Revenue in Cell Therapy Business (2019-2020)84 12.6 Fujifilm Cellular Dynamics85 12.6.1 Fujifilm Cellular Dynamics Company Details85 12.6.2 Fujifilm Cellular Dynamics Cell Therapy Introduction86 12.6.3 Fujifilm Cellular Dynamics Revenue in Cell Therapy Business (2019-2020)86 12.7 JCR Pharmaceuticals87 12.7.1 JCR Pharmaceuticals Company Details87 12.7.2 JCR Pharmaceuticals Cell Therapy Introduction88 12.7.3 JCR Pharmaceuticals Revenue in Cell Therapy Business (2019-2020)89 12.8 Beike Biotechnology89 12.8.1 Beike Biotechnology Company Details89 12.8.2 Beike Biotechnology Cell Therapy Introduction90 12.8.3 Beike Biotechnology Revenue in Cell Therapy Business (2019-2020)90 12.9 Golden Meditech91 12.9.1 Golden Meditech Company Details91 12.9.2 Golden Meditech Cell Therapy Introduction91 12.9.3 Golden Meditech Revenue in Cell Therapy Business (2019-2020)92 12.10 Guanhao Biotech92 12.10.1 Guanhao Biotech Company Details92 12.10.2 Guanhao Biotech Cell Therapy Introduction93 12.10.3 Guanhao Biotech Revenue in Cell Therapy Business (2019-2020)94 13 ANALYSTS VIEWPOINTS/CONCLUSIONS95 14 APPENDIX96 14.1 Research Methodology96 14.1.1 Methodology/Research Approach96 14.1.2 Data Source99 14.2 Disclaimer102 14.3 Author Details102

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Visit link:
Cell Therapy Market Brief Analysis and Application, Growth by 2026 - Scientect

Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL? – Cancer Therapy Advisor

Efficacy ofchimeric antigen receptor (CAR) T-cell (CAR-T) therapies in chronic lymphocytic leukemia (CLL) have lagged behind the efficacy they appear to have in other hematological malignancies such as acute lymphoblastic leukemia or diffuse large B-cell lymphoma.

Theres a growing recognition that some of the CAR-T shortfalls in CLL are due to an impaired fitness of T cells in CLL patients. Some research has shown, however, that sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.1 Such findings have galvanized interest in approaches to enhance this T-cell population during the immunotherapy manufacturing process as a possible route for overcoming treatment resistance.

Now, a small study in the International Journal of Cancer reported that culturing CLL patients T cells with the tyrosine kinase inhibitor ibrutinib which among other effects, inhibits a pathway involved in T-cell differentiation boosted the viability, function, and expansion of CLL patient-derived CAR T cells as well as enriching them with a less-differentiated phenotype.2

In culture, they could prevent the T cells from differentiating when they treat with ibrutinib, and thats [creating] the seed population that you want for adoptive T-cell therapy, noted Joseph A. Fraietta, PhD, assistant professor of microbiology and director of the solid tumor immunotherapy laboratory at the center for advanced cellular therapeutics at the University of Pennsylvania, who wasnt involved in the research. If the results hold up, this could be a giant step forward, I think, for these patients who need CAR T-cell therapy to get into long-term durable remission.

For the study, a team of researchers from Germany extracted peripheral blood mononuclear cells from 8 CLL patients and 9 healthy people. They cultured them into CD19-directed CAR-T cells using standard protocols, but under 2 different conditions: 1 without ibrutinib, and 1 in the presence of ibrutinib.

In a series of analyses, the authors found that although cell proliferation during CAR-T generation was generally much lower in CLL-derived cells compared with healthy ones, the absolute numbers of CLL patient-derived CAR-T cells were substantially higher when they were cultured with ibrutinib supplementation. The ibrutinib-supplemented CAR T cells also produced more cytokines in an assay in which the cells were stimulated with a B lymphoblast cell line, and also expressed fewer cell exhaustion markers such as LAG-3, TIM-3, and PD-1, which can impede T-cell function.

Cultivating the CLL patient-derived and healthy cells with ibrutinib had no impact on the proportions of CD4+ and CD8+ T cells, but it did on the proportion of early T cells that were in a less-differentiated state. Stem cell memory-like T cells and what the authors called naive-like T cells are thought to be important for the generation of CAR T cells and their long-term persistence in vivo. Ibrutinib supplementation enriched both products derived from CLL patients and from healthy people with these phenotypes, the authors reported.

See original here:
Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL? - Cancer Therapy Advisor

Stem Cell Source Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2024 (Based on 2020 COVID-19 Worldwide…

2020 September, Magarpatta SEZ, Pune, ReportsnReports, one of the worlds prominent market research firms has released a new report on Global Stem Cell Source Market. The report contains crucial insights on the market which will support the clients to make the right business decisions. This research will help both existing and new aspirants for Stem Cell Source Market to figure out and study market needs, market size, and competition. The report talks about the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats faced by Top key players.

Get Free Sample PDF Copy of Stem Cell Source Market with Figures, Graphs and Tocs:https://www.reportsnreports.com/contacts/requestsample.aspx?name=3515209

The report also includes the impact of ongoing global crisis i.e.COVID-19on the Stem Cell Source Market and what the future holds for it. The published report is designed using a vigorous and thorough research methodology andReportsnReportsis also known for its data accuracy and granular market reports.

Summary

The global Stem Cell Source market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025.

Further key aspects of the report indicate that: Chapter 1: Market Definition and Segment by Type, End-Use & Major Regions Market Size Chapter 2: Global Production & Consumption Market by Type and End-Use Chapter 3: Europe Production & Consumption Market by Type and End-Use Chapter 4: America Production & Consumption Market by Type and End-Use Chapter 5: Asia Production & Consumption Market by Type and End-Use Chapter 6: Oceania Production & Consumption Market by Type and End-Use Chapter 7: Africa Production & Consumption Market by Type and End-Use Chapter 8: Global Market Forecast by Type, End-Use and Region Chapter 9: Company information, Sales, Cost, Margin, news etc. Chapter 10: Market Competition by Companies and Market Concentration Ratio Chapter 11: Market Impact by Coronavirus. Chapter 12: Industry Summary

Market Segment as follows:

Key Companies BD Bioscience Beckman Coulter Ge Healthcare Merck Millipore Miltenyi Biotec Pluriselect Life Science Sigma-Aldrich Corporation Stemcell Technologies Terumo BCT Thermo Fisher ScientificCompany 13

Key Types Reagent Instrument Others

Key End-Use Hospital Biotechnology Research Center Others

This report can be dispatched within 24-48 Hours.

Enquire for More Information on Stem Cell Source Market:https://www.reportsnreports.com/contacts/discount.aspx?name=3515209

The global Stem Cell Source Market is expected to witness a promising growth in the next few years. The rising level of competition among the leading players and the rising focus on the development of new products are likely to offer promising growth opportunities throughout the forecast period. The research study on the global Stem Cell Source Market offers a detailed overview, highlighting the key aspects that are expected to enhance the growth of the market in the near future. The key segmentation and the competitive landscape of the market have also been mentioned at length in the research study.

This report studies the Stem Cell Source Market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Stem Cell Source Market by product type and applications/end industries. These details further contain a basic summary of the company, merchant profile, and the product range of the company in question. The report analyzes data regarding the proceeds accrued, product sales, gross margins, price patterns, and news updates relating to the company.

Full Report available @https://www.reportsnreports.com/purchase.aspx?name=3515209

The report helps to identify the main Stem Cell Source Market players. It assists in analyzing Stem Cell Source Market competitive environment, including company overview, company total revenue, market opportunities, value, production sites and facilities, SWOT analysis, product details. The study also reveals the sales, revenue and market share for each market player included in this report for the period of 2015-2020. It also helps to ascertain the growth drivers and future prospects for the forecast timeline.

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Stem Cell Source Market forecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, growth drivers of by analyzing the historical overall data of the considered market segments.

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

We provide 24/7 online and offline support to our customers.

E-mail: [emailprotected]

Phone: +1 888 391 5441

See original here:
Stem Cell Source Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2024 (Based on 2020 COVID-19 Worldwide...

Be The Match Presents "Sickle Cell Connect" Virtual Event Series To Raise Awareness Of Treatment Options And Marrow Transplants As A Cure…

MINNEAPOLIS, Sept. 4, 2020 /PRNewswire/ -- Sickle Cell warrior Tahir "StayFresh" Ali of Atlanta, Ga., visits the hospital twice monthly for blood transfusions to reduce complications from sickle cell disease, and manage his potential risk of organ damage or stroke. The 35-year-old music producer and manager estimates he has spent several years of his life in the hospital undergoing treatment for sickle cell disease. Finding a perfectly matched marrow or blood stem cell donor could give StayFresh a chance to live life free of sickle cell and the many complications that the disease presents.

September is Sickle Cell Awareness Month, and Be The Match, the National Marrow Donor Program, is launching several campaigns to help people to learn more about the disease, and take action to help those searching for a matching blood stem cell or marrow donor.

StayFresh is like 100,000 African Americans who battle sickle cell disease, an often-misunderstood genetic disease that is "invisible" because unlike many illnesses, people with sickle cell disease can lead active lives. However, people with severe sickle cell can face debilitating episodes of pain crisis and life-threatening complications. StayFresh is working with Be The Match to rally more Black and African Americans to join the Be The Match Registry.

Be The Match is also hosting a three-part virtual event series to raise awareness about sickle cell disease, provide free resources for patients and families affected by sickle cell, discuss treatment options, and the need for more Black donors on the Be The Match Registry. The event series and more information can be found at: SickleCellConnect.com.

"We are grateful to have a dedicated Patient Services team that is able to produce these informative virtual events to help sickle cell patients and their caregivers learn how to access free resources and advocate for themselves as they navigate their disease," said Erica Jensen, Senior Vice President of Be The Match Member Engagement, Enrollment and Experience. "Nobody with sickle cell disease has to walk alone. Be The Match has a peer connect program, free professional counseling, nurse navigators and strong partnerships with organizations like The Sickle Cell Community Consortium and My Three Sicklers Foundation to ensure we can connect caregivers and sickle cell warriors with the resources they need to best manage this disease."

According to the Centers for Disease Control, sickle cell disease is the most common inherited disease, affecting 1 in 365 Black or African Americans and 1 in 16,300 Hispanic Americans. With sickle cell disease, oxygen-carrying red blood cells are misshapen, hard and sticky, which can result in them getting stuck in blood vessels and clog them. This can cause severe pain crisis, infections, organ damage, low blood counts, stroke and other serious health problems.

Be The Match has also launched an informative online video called "You Are My Match" to raise awareness of the need for more Black or African American donors on the Be The Match Registry to help Black patients battling sickle cell disease find a potentially life-saving match. The video features a 4-year-old girl named Ruby from Lubbock, TX, who has been hospitalized more than 24 times and had three surgeries due to her sickle cell. Ruby's doctors are recommending a blood stem cell or marrow transplant due to the severity of her condition, but she does not have a perfect match on the Be The Match Registry.

Part of the challenge Black patients like Ruby face when searching for a perfect match is low representation of Black or African Americans on the Be The Match Registry. Of the 22 million potential donors on the Be The Match Registry, just 4 percent are Black or African American. Because ethnicity plays a role in finding a match, Black patients will only find a perfect match 23% of the time, which is much lower than other ethnicities, such as White patients, who will find a match 77% of the time.

To learn how to access free resources, read stories about people cured of sickle cell disease following a marrow or stem cell transplant and to join the Be The Match Registry, visit: http://www.sicklecellconnect.com.

Virtual Event Series:Episodes will be streamed via http://www.sicklecellconnect.comwebpage and viewable on Be The Match Social Channels.

Episode 1: What is sickle cell disease?September 10thfrom 12:00 12:30 p.m. CDT We'll chat about sickle cell disease basics with pediatric hematologist Staci Arnold, MD, hear sickle cell warrior Genesis' storyandlearn about barriers and disparities that sickle cell patients face from the Health Equity Manager at Be The Match.

Episode 2: Living with sickle cell diseaseSeptember 17th from 12:00 12:30 p.m. CDT We'll chat with a Be The Match Patient Navigator and Social Worker about the free resources available to sickle cell disease patients and hear from the founder of My Three Sicklers Foundation.

Episode 3:The future of sickle cell diseaseSeptember24th from 12:00 1:00p.m. CDT We'll cover transplant and gene therapy with Staci Arnold, MD and a certified genetic counselor from BeTheMatch. Hear about our policy efforts for sickle cell disease, meet sickle cell warriorDakhiyon, seehow Nia Imani Franklin, former Miss America, is advocating for more diverse donors on the Be The Match Registry, plus watch a live swabbing event!

Continue reading here:
Be The Match Presents "Sickle Cell Connect" Virtual Event Series To Raise Awareness Of Treatment Options And Marrow Transplants As A Cure...

Betty Lin-Fisher: Men, take care of your health – Akron Beacon Journal

Tom Fister has been a doting husband to his wife of 41 years, Sue.

Sue has been in and out of the hospital in the last year with complications after her second bout of acute myelogenous leukemia (AML). Last year, she had an umbilical cord stem cell transplant. That was 15 years after she first had the same leukemia.

Tom Fister, 69, was so focused on his wife and her care that the self-described "hard-headed man" ignored his own health to the point where he could have died, his doctor said.

The Copley man was on medication for high-blood pressure, but otherwise did not know he had other health complications.

He was slowly having a harder time walking from the parking deck at University Hospitals to go visit his wife daily before the COVID-19 virus shut down access to the hospitals and the shelter-in-place orders went into effect.

On March 13, Fister got up, showered and went in and checked himself into the emergency room.

"I spent a month in the hospital and three and a half weeks in the ICU," he said. "I pretty much just ran myself down."

When he went to the hospital, doctors discovered he was in acute heart failure and kidney failure and had pulmonary hypertension and severe aortic stenosis, which is a severe narrowing of the aortic valve, said Dr. Joseph Lahorra, a cardiothoracic surgeon and chairman of the Cleveland Clinic Akron General heart, vascular and thoracic department.

Severe aortic stenosis is a chronic and progressive disease that is fatal if untreated, Lahorra said.

"He basically was not following up with anybody because he was taking care of his wife," Lahorra said. Fister also was concerned if he got evaluated for his medical conditions, it would take away from his focus on his wifes care.

Fister is "a very altruistic guy," said Lahorra, and a prime example of men represented in a Cleveland Clinic study released earlier this week.

The national survey by Cleveland Clinic revealed that the COVID-19 pandemic is affecting both the mental and physical health of men. Some men are negatively impacted, while others are making healthier choices.

In an online survey among about 1,000 U.S. males 18 and older, Cleveland Clinic found that 77% of men report their stress level has increased as a result of COVID-19, 59% of men say they have felt isolated during the pandemic and nearly half (45%) of men say their emotional/mental health has worsened during the pandemic.

The survey was issued as part of Cleveland Clinics fifth annual educational campaign, "MENtion It," which aims to address the fact that men often do not talk about health issues or take steps to prevent them.

This year, the Clinic wanted to see what sort of effect the pandemic has had on men over the past six months and what their outlook is.

Here are a few other findings:

Three-in-five men (59%) feel COVID-19 has had a greater negative impact on their mental health than the 2008 recession.

66% of men say they rarely talk about the impact COVID-19 has had on their mental health.

Half of men (48%) have put off seeing a doctor for non-COVID-19 related health issues. That is even higher among men ages 18 to 34 (56%).

While some are struggling, COVID-19 has also inspired healthier habits in some. Nearly half of men (45%) feel healthier now and 22% are exercising more.

While 64% dont see an end to the COVID-19 outbreak in sight, the majority (71%) still remain optimistic about the future as the world continues to battle COVID-19, suggesting the pandemic hasnt dampened spirits completely.

"We couldnt take the temperature on the state of mens health this year without focusing on the one thing that has affected every person in this country and beyond," said Dr. Eric Klein, chairman of Cleveland Clinics Glickman Urological and Kidney Institute. "Many men are finding themselves in new and different roles as a result of this pandemic; for example, they are out of work or are working around the clock at home looking after kids with their partners all while worrying about their familys health and their own health. Its no surprise that mental health rose to the top as a critical issue in this years survey.

"We want to remind men that their health shouldnt take a back seat, especially during a pandemic," Klein said. "If youre experiencing symptoms that indicate a real health issue, dont be afraid to come to the hospital or schedule an appointment with a health care provider, either virtually or in person. Your health is too important not to."

For Fister, once he got to the hospital, doctors had to stabilize his health, including getting him on dialysis three times a week.

Doctors wanted to do whats called a TAVR procedure, a relatively new procedure that has been a paradigm shift for patients and doctors, Lahorra said. The procedure eliminates the need for open-heart surgery in some patients, which would obviously require a much-longer recovery time. In a TAVR procedure, the aortic valve is opened up through the groin and patients can go home the next day.

But for Fister, even proceeding with the TAVR was considered risky, given his initial medical issues. So doctors temporarily opened the valve with a balloon to give him a few months to stabilize his other health issues. He had the TAVR procedure in July, performed by Lahorra and cardiologist Dr. Anmar Kanaan.

Doctors also wanted to keep Fister out of the hospital during the height of the COVID-19 pandemic last spring because he was a severe risk.

"He is the exact patient who if he got COVID, he would not do well. He would do very poorly. We discussed that with him," Lahorra said.

Hospitals have seen patients who were avoiding getting care for fear of contracting COVID-19, to the detriment of their health, he said.

But now, however, data have shown hospitals are safe, even for people at high riks for COVID-19 complications, he said.

"This is a vital message to get out. Continue with your routine health care and certainly for more urgent acute problems, definitely get seen. The environment is very safe," Lahorra said.

Fister is grateful for what he calls his "medical miracle." He feels great now and just got trained to do peritoneal dialysis at home. His wife, Sue, was just moved to a rehab facility and he hopes she will be able to come home soon.

Fister said hes a fairly private person, but agreed to talk about his medical journey because "there are people who might be helped from this," he said. "If I can help some people, thats why were talking today."

Beacon Journal consumer columnist and medical reporter Betty Lin-Fisher can be reached at 330-996-3724 or blinfisher@thebeaconjournal.com. Follow her @blinfisherABJ on Twitter or http://www.facebook.com/BettyLinFisherABJ and see all her stories at http://www.beaconjournal.com/topics/linfisher

Continued here:
Betty Lin-Fisher: Men, take care of your health - Akron Beacon Journal

Seniors suffer the most from antiquated FDA approval process | TheHill – The Hill

Americans have been heartbroken as report after report shines a light on the COVID-19 pandemic sweeping through nursing homes and decimating some senior community populations. Not only have our seniors been struck in their final years with a hideous virus, but they are also the victims of an antiquated drug approval process that is nearly six decades old and in need of drastic improvement.

The fact is, we already have a model that works, which can be adapted for use in America with minor changes.

While some streamlining of the FDA approval process has taken place, especially in the midst of the HIV/AIDS epidemic, it is still denying our seniors, their families and physicians the opportunity to make informed choices about the level of risk they are willing to take (advised by their doctors) with promising but not officially approved treatments, pharmaceuticalsand therapies. Let seniors, and anyone dealing with a serious medical condition, have the opportunity to make informed decisions.

The biopharmaceutical industry has also seen major changes since 1962, when Congress passed foundational legislation to ensure that consumers would not be the victims of unsafe and ineffective medications. The advent of biotechnology, gene therapy, artificial intelligence, and the internet contributed to improved treatment results for patients and longer life spans. Meanwhile, the FDA has made only incremental improvements (with exceptions) to the rules which shorten the review time required for a drug to receive FDA approval, including Priority Review, Accelerated Approval, Fast Track and Breakthrough Therapy Designation.

These programs reflect the difficulty the FDA and Congress have in balancing the need to protect the American people against the need to make new vaccines and treatments available to those who need them, especially when dealing with life and death and serious illnesses such as the novel coronavirus.

We do not need to reinvent the wheel; We just need to expand an existing program.

In 2014 the Japanese Health Ministry established an accelerated conditional approval pathway for regenerative medicines that enables more patients to access products like tissue grafts and stem cell therapies that have demonstrated initial safety and efficacy, but have not completed the many years of standard clinical testing required under the countrys formal approval process. This program,which is especially beneficial to Japanese seniors,actually builds upon the Parallel Track approval process that was initiated by the FDA in 1992 to allow AIDS/HIV drugs to be accessible immediately following successful safety testing, but before completion of the more rigorous and time-consuming efficacy trials. On Oct. 5, 1992 the first drug to be approved under Parallel Track, stavudine, became available, extending the lives of thousands of sick people before eventually receiving standard FDA approval.

By expanding Parallel Track, all drugs that treat serious and life-threatening illnesses would be conditionally approved once early stage clinical trials suggest that a medicine has a safety profile consistent with the severity of the disease being treated and a likelihood of patient benefit. All physicians would then be able to prescribe such treatments to fully informed patients. As part of the program, the productdeveloper would be requiredto collect relevant data and results from patient use. In addition, a public database would be established where physicians prescribing Parallel Track approved therapies would be required to post anonymized treatment results.

The public database would enable doctors, patients, and the public health community to quickly learn about the successes, failures, benefits, and side effects that patients using Parallel Track approved treatments are experiencing. The FDA already collects real-world data on the side effects associated with approved medicines, which it uses to monitor safety and keep labels updated. Expanding this program would result in additional real time comprehensive patient data.

Now is the time for the United States to take this bold step forward and create an accelerated approval pathway for developmental treatments that give patients and doctors greater control over their health care. ExpandingParallel Track to include a publicly available database of real-world treatment results would accelerate biopharmaceutical innovation, reduce development costs and lower drug prices while expediting new standards of care and cures.

Seniors cant wait 10-12 years to have a drug approved, nor can they pay for drugs that are priced to quickly recoup the $2.6 billion dollars it costs to gain approval. With the expansion of Parallel Track, more seniors will be able to walk out of hospitals and live longer healthier lives.

Diane Abbitt is a Los Angeles attorney who played a leading role in the 1990s campaign to secure early access to not-yet-FDA-approved drugs to treat AIDS. Bartley J. Madden is an independent researcher in Florida. Japans conditional approval pathway was based on a proposal in his book, Free to Choose Medicine: Better Drugs Sooner at Lower Cost.

More:
Seniors suffer the most from antiquated FDA approval process | TheHill - The Hill

Father of Three with Incurable Cancer is Helping Researchers Get One Step Closer to a Cure – The Suburban Newspaper

In 2016, Danny Wade, a successful marketing professional and an active and doting father to his three young children, aged 11, 8 and 6, checked himself into the emergency department when he began experiencing severe, inexplicable bone pain and unusual fatigue.

Two days later, after undergoing a battery of tests, Danny was diagnosed with multiple myeloma, a little-known and incurable cancer of the plasma cells. He was just 42 years old.

"I was shocked when I got the news, Danny recalls. What upset me most was when the doctor told me that the average life expectancy for myeloma patients was only five to seven years. The thought that I would not see my children grow up was devastating. I knew I had to fight for my life.

Thats exactly what Danny has been doing. Within six months of being diagnosed, Danny went through a difficult high-dose chemotherapy regimen to prepare for an autologous stem cell transplant using his own stem cells. Then in 2017 after further tests, Dannys doctors recommended that his best option for survival was to undergo another transplant with stem cells from a healthy donor. He took his doctors advice and underwent the procedure. Fortunately, he was eligible to participate in a clinical trial at Maisonneuve-Rosemont Hospital where he received a breakthrough therapy involving bi-weekly injections that he will continue to take for a year.

Dannys condition is relatively stable at this time, and he extremely thankful to still be alive. He is thrilled to watch his children grow and to resume being an active part of their lives. He credits his survival to the life-saving treatments that he has access to and the love and support he receives from his partner, Anik. With my beloved Anik by my side, Ive had the courage to get through this nightmare and to have faith that I can get through whatever else the future holds.

Danny is eager to do what he can to help others living with myeloma. I made a promise that once I was doing well, I would do everything in my power to help find a cure so that other patients dont have to live through the horrors I have," says Danny. Danny is a member of the organizing committee of the Montreal Support Group, and recently co-founded the South Shore Myeloma Support Group.

Over the past four years, Danny has seen, first-hand, the life-changing impact that advances in myeloma research are having on the lives of those living with this incurable cancer. Thats why he and his family are more intent than ever to raise as much awareness and funds for myeloma as they can, and will be participating in Myeloma Canadas 12th annual Montreal Multiple Myeloma March on Sunday, September 20, at 10 am.

This years Montreal March has been modified to help stop the spread of COVID-19. In compliance with physical distancing measures, participants are encouraged to hold their own walk in their neighbourhood at the same time as the regularly scheduled March on September 20. Danny and his fellow Montreal Marchers have set their fundraising goal at $60,000 to help further crucial research for this deadly blood cancer that affects nine new Canadians every day.

Myeloma research has produced extremely promising results over the past two decades. In fact, for the first time, theres a cure in sight, says Dr Richard LeBlanc, Medical Hematologist and Oncologist, and holder of the Myeloma Canada Chair in Multiple Myeloma Research at the Universit de Montral. We cant afford to let the current situation stop the progress weve made and put vulnerable people living with myeloma at risk, which is why its more crucial than ever to invest in research and find a cure.

The Multiple Myeloma March, Myeloma Canadas flagship fundraiser is now in its 12th year. The annual five-kilometer event brings Canadian communities together to raise essential funds for research and to help improve the lives of all Canadians impacted by myeloma. Montreal is one of a record 33 communities across the country to be included in this years Multiple Myeloma March. The national fundraising goal is set at $650,000. To learn more about how this event will be working, please click here.

While this years March will undoubtedly be different because of the pandemic, its crucial to stay positive, says Martine Elias, Executive Director of Myeloma Canada. Fundraising has taken a huge hit for many organizations. We need to do all we can to increase awareness and raise essential funds for research that will improve the lives of Canadians impacted by myeloma, and bring us closer to a cure, Martine added. As we mark Myeloma Canadas 15th anniversary, we celebrate the strength of our incredible community. More than ever, were counting on our supporters to help us achieve our goal of $650,000. Canadians impacted by this incurable cancer are depending on us.

This year, a minimum of 50% of funds raised by the Multiple Myeloma March will go directly to support Myeloma Canadas Myeloma Research Priority Setting Partnership (PSP), the first program of its kind in myeloma. The PSP will use input provided by the Canadian myeloma community to identify and define investments in myeloma research over the next 18 months. The balance raised will go toward supporting various myeloma research projects and initiatives that are pivotal for improving quality of life and moving the needle toward a cure.

Multiple myeloma, also known as myeloma, is the second most common form of blood cancer. Myeloma affects a type of immune cell called the plasma cell, found in the bone marrow. Every day, nine Canadians are diagnosed, yet in spite of its growing prevalence, the disease remains relatively unknown. While there is no cure, people with myeloma are living longer and better lives, thanks to recent breakthroughs in treatment. To find the cure, more funding and research are required. To learn more, or to donate, please visit http://www.myeloma.ca

Myeloma Canada

http://www.myeloma.ca

AB

Continue reading here:
Father of Three with Incurable Cancer is Helping Researchers Get One Step Closer to a Cure - The Suburban Newspaper

Editorial: UT Healths new teaching hospital will boost region – San Antonio Express-News

A planned 144-bed teaching hospital on the UT Health San Antonio campus slated to open in the spring of 2024 will boost enrollment for many health programs so crucial for the region and state.

The medical school alone could see an increase of 22 students in each enrollment class. The number of medical residents could grow by 100 to 130 slots by 2027. Currently, 1,000 residency slots are offered through UT Health San Antonio.

This is great news for medical and other students training for health professions who want to complete their education in Texas. It will help address the shortage of providers in Bexar County and across the state. Historically, many doctors remain in the communities where they complete their medical training.

The San Antonio hospital would become the fourth operated by the University of Texas System. The others are in Dallas, Galveston and Tyler.

Most of the UT System health science centers have partnerships with independently managed hospitals in their communities.

Most new hospital projects arrive with much fanfare. This project has been quietly moving along over the past year with little public awareness or discussion.

The University of Texas System regents last month placed the nearly $400 million project on its capital improvement program and are expected to appropriate construction funds at their November meeting.

The hospital will be located on 12 acres in the South Texas Medical Center provided by the San Antonio Medical Foundation. The eight-story hospital will be adjacent to the Mays Cancer Center, formerly known as the Cancer Therapy and Research Center. The jointly run UT Health San Antonio-MD Anderson program is a National Cancer Institute-designated research center. The hospital and the cancer center will be connected by a skybridge.

A 530-space parking garage is also included in the project.

Background information provided to the regents describes a high-acuity hospital offering treatment programs in cancer, neurosciences, orthopedics, urology, thoracic surgery and bariatrics.

A distinct, competitive advantage of the hospital will be the unique leading-edge therapies and early-phase clinical trials in the many disciplines in which the university has expertise, including immunologic and stem cell therapies in oncology and diabetes, the backgrounder states.

The construction of a second teaching hospital in San Antonio raises concerns about the multibillion-dollar investment taxpayers have made in the Bexar County Hospital District, which includes University Hospital and some two dozen University Health System clinics.

University Hospital has long been the primary teaching hospital for UT Health San Antonio, and much of its recent expansion including the new 400-bed Womens and Childrens Hospital now under construction alongside University Hospital has been in large part to accommodate the patients seen by UT Health San Antonio doctors.

Will the two be duplicating services and competing for patients?

UT Health San Antonio President William L. Henrich and Bexar County Judge Nelson Wolff said the two hospitals will work in partnership. The hospital district and UT officials are negotiating a memorandum of understanding to that effect, Wolff said.

Henrich said the new hospital will not replicate any services and will complement what is currently offered. He said the new facility will allow for the expansion of the health science centers three primary missions clinical care, biomedical research and education.

Our clinical practices have been growing 8 to 10 percent a year, Henrich said. We have about $300 million in research on campus, and we need more access to clinical trials. Sophisticated clinical trials in cancer, rheumatology, gastroenterology and this hospital will afford us the opportunity to carry out those trials, and that will be a unique feature of this hospital.

In addition, the new hospital is expected to create 750 to 850 new jobs.

This is an important project for San Antonio and Texas. It will expand higher education opportunities, help address the doctor shortage in the state and provide a lift to the local economy by creating skilled jobs.

We look forward to a thriving partnership between UT Health and the University Health System.

Originally posted here:
Editorial: UT Healths new teaching hospital will boost region - San Antonio Express-News

There is a dire need for ‘donors of colour’ in the fight against blood disorders – Health24

Compiled by Gabi Zietsman | Health24

04 Sep 2020, 02:45

Two hikers are going to great heights to increase awareness of blood disorders, and the urgent need for bone marrow donors in South Africa.

In a symbolic hike up the country's highest peak in the Drakensberg range, adventurer and bone marrow donor Clayton Coetzee and expert mountaineer and author Gavin Raubenheimer will be tackling Mafadi from 7 to 9 September in honour of those who have helped save the lives of countless people suffering from blood disorders.

Bone marrow donation is close to my heart as one of my dearest friends got sick with Acute Myeloid Leukaemia (AML) several years ago," says Coetzee. "Its then when I heard about the SA Bone Marrow Registry and the life-saving work that they do, and I decided to sign up as a donor."

READ | Could smoking lead to this blood disorder?

Increase in cases

Blood cancer is one of the most common of these disorders and affects children the most, while other blood disorders include non-Hodgkin lymphoma (NHL).

Unfortunately, according to the Search Coordinator for the SA Bone Marrow Registry (SABMR) Alicia Venter, these diseases have increased in the last decade 45% in NHL cases and 26% in leukaemia cases.

"While recommended, prevention efforts, such as lifestyle changes, tend to be less effective for hematologic malignancies than for other cancers, which makes a blood stem cell transplant a patients only hope for survival," says Venter.

In order to be a suitable bone marrow donor, your human leukocyte antigen (HLA) needs to match someone in need. HLAs are genes in a human's DNA that help regulate immunity and affect whether or not a recipient's body will reject a transplant.

READ MORE | Bone marrow transplants less risky now

Need more non-white donors

Finding a match, however, isn't as easy as swiping on a dating app and SAMBR has a serious lack of diversity in the donor database. Currently, there are only about 74 000 local donors on the South African Bone Marrow Registry.

In South Africa, there is a dire need for donors of colour," explains Venter.

"When it comes to matching HLA types, a patients ethnicity plays an important role as HLA markers are inherited. Some ethnic groups have more complex tissue types than others, therefore finding a match is most likely to come from someone of the same ethnic group."

'As easy as giving blood'

The hike is supposed to be symbolic of the uphill battle that faces those suffering from blood disorders, including finding a suitable donor to increase their chances of survival. Besides the gruelling experience, SAMBR will also be doing a cheek swab drive at the same time in Agulhas, Western Cape, and Musina, Limpopo, to help boost donor registrations.

According to Coetzee, it's easy to be registered as a donor all it takes is a cheek swab. If you do match with someone, it's "almost as easy as giving blood".

If a match is found, a donor will undergo a full medical exam to look for any exclusionary factors like obesity, HIV status, other chronic conditions and viral infections. Once cleared, the donor goes on a five-day treatment of injections to increase the number of stem cells in the bloodstream.

On the fifth day, the donor will be admitted to a hospital and connect to a cell separator machine, where the bone marrow donation would be made. The collected samples then has 72 hours to be transplanted to the receiving patient.

In South Africa, doctors will seldom collect bone marrow straight from the source.Possible side effects to receiving the injections may include headache, bone pain and flu-like symptoms.

I want people to know that blood diseases can affect anyone, regardless of ethnicity or gender. Extending beyond our boundaries or comfort zones like climbing Mafadi can be hard, but imagine the indelible difference the act of becoming a donor can have on someone elses life and their loved ones, says Coetzee.

You can follow the hikers' journey onSAMBR's Facebook page.

If you are between the ages of 18 and 45 and want to become a donor, contact the SABMR on021 447 8638 oremail:donors@sabmr.co.za.For more info and how to donate, visit their website.

READ MORE | Leukaemia survivor stories

Image credit: Pixabay

Read more here:
There is a dire need for 'donors of colour' in the fight against blood disorders - Health24